What is William Blair’s Estimate for FibroGen Q1 Earnings?

FibroGen, Inc. (NASDAQ:FGEN) – Investment analysts at William Blair issued their Q1 2025 earnings per share estimates for FibroGen in a report issued on Tuesday, March 18th. William Blair analyst A. Hsieh anticipates that the biopharmaceutical company will post earnings of $0.02 per share for the quarter. The consensus estimate for FibroGen’s current full-year earnings is ($0.80) per share. William Blair also issued estimates for FibroGen’s Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.88) EPS, FY2026 earnings at ($0.86) EPS and FY2027 earnings at ($0.72) EPS.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Monday, March 17th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.08). The company had revenue of $3.14 million for the quarter, compared to the consensus estimate of $24.91 million.

Several other brokerages also recently issued reports on FGEN. StockNews.com assumed coverage on shares of FibroGen in a research note on Friday, March 14th. They issued a “hold” rating for the company. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of FibroGen in a research report on Tuesday.

FibroGen Price Performance

Shares of FGEN stock opened at $0.32 on Thursday. The company has a fifty day moving average price of $0.49 and a two-hundred day moving average price of $0.43. FibroGen has a one year low of $0.18 and a one year high of $2.80. The stock has a market cap of $31.74 million, a P/E ratio of -0.26 and a beta of 0.82.

Hedge Funds Weigh In On FibroGen

Large investors have recently modified their holdings of the stock. Geode Capital Management LLC increased its position in FibroGen by 3.1% during the third quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock worth $433,000 after acquiring an additional 32,884 shares during the period. Two Sigma Securities LLC acquired a new position in shares of FibroGen during the 4th quarter worth approximately $27,000. FMR LLC increased its holdings in shares of FibroGen by 21.8% during the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock worth $153,000 after purchasing an additional 68,569 shares during the period. XTX Topco Ltd raised its position in shares of FibroGen by 423.8% in the fourth quarter. XTX Topco Ltd now owns 96,025 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 77,693 shares in the last quarter. Finally, Velan Capital Investment Management LP bought a new stake in shares of FibroGen in the fourth quarter valued at approximately $42,000. 72.71% of the stock is owned by institutional investors.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.